Brandon Capital Partners related stories
All articles and analysis
Australia’s Medical Research Commercialisation Fund invests in AuspherixAuspherix Pty Ltd said Thursday it has secured another AU$1 million (US$878,215) in a series A financing from Australia’s Medical Research Commercialisation Fund. Auspherix, of Sydney, is an early stage anti-infectives company developing antibiotics to treat resistant bacterial disease.
- Irish biotech firm Heart Metabolics snags $20 mln Series A funds
Heart Metabolics said Thursday that it has closed $20 million in Series A funding. The investors were venBio, Seroba Kernel Life Sciences, Brandon Capital Partners (on behalf of AustralianSuper) and AshHill. Based in Dublin, Ireland, Heart Metabolics is a biotech firm focused on developing treatments for cardio-metabolic diseases.
- Novo A/S leads $45 mln Series C funding round in Spinifex Pharmaceuticals
Novo A/S has led a $45 million Series C funding round in Spinifex Pharmaceuticals, a developer of pain drugs. The funding round was joined by new investor Canaan Partners. Existing investors GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest also participated in the funding round. Heath Lukatch and Steve Collins representing Novo A/S and Brent Ahrens of Canaan Partners will join the Spinifex board.
- MRCF invests in antibiotics start-up Auspherix
Auspherix, an early stage anti-infectives company has launched with AU$1 million in start-up financing from Australia’s Medical Research Commercialisation Fund. Auspherix will in-license intellectual property from the ithree institute at the University of Technology Sydney, emerging from research led by Professor Ian Charles, director of the ithree institute together with Dr Dagmar Alber, ithree Senior Research Fellow.
- PolyActiva Inks $9.5M
PolyActiva has raised AUD $9.2 million ($9.5 million) in Series B financing. Investors including the Medical Research Commercialisation Fund, Brandon Biosciences Fund 1, Yuuwa Capital and angel investors. The Australian company will use the infusion to continue preclinical and clinical development programs, which are aimed at treating eye infections.
- Spinifex Pharmaceuticals Closes $19M VC Round
Australia’s Spinifex Pharmaceuticals has closed its Series B round after adding an additional AU$6.25 million ($6.5 million) from GBS Venture Partners, Brandon Capital Partners, Uniseed Management and UniQuest. The total amount raised in the round was $19 million. The money will help fund the development of Spinifex’s pain management drug.
- Week in deals, April 12, 2010
Summary of tech companies and other startups in North America that raised venture financing in the past week
- Signostics Raises $5 Million
Signostics Inc., a developer of palm-sized ultrasound devices for medical applications, has raised $5 million in new VC funding. No investor information was disclosed. The company previously raised $14 million from firms that included Brandon Capital Partners, Playford Capital and Terra Rossa Capital. It has offices in Australia and Silicon Valley.
- peHUB Wire: Wednesday, March 31, 2010
Random Ramblings
- peHUB Wire: Wednesday, March 31, 2010
Random Ramblings